Volta Medical宣布将在美国加利福尼亚州圣地亚哥举行的2025年心律学会上发表演讲-动脉网

Volta Medical Announces Presentations at Heart Rhythm Society 2025 in San Diego, CA, USA

CISION 等信源发布 2025-04-15 20:00



可切换为仅中文







Co-founder Dr. Clément Bars to present on additional TAILORED-AF clinical trial findings

联合创始人克莱门特·巴尔斯博士将介绍TAILOR-AF临床试验的更多研究结果。

Dr.

博士

John Hummel

约翰·胡梅尔

to present the initial outcomes of the RESTART trial focused on the underserved patient population requiring re-ablation

展示针对需要再次消融的未充分服务患者群体的RESTART试验的初步结果

MARSEILLE, France

法国马赛

，

April 15, 2025

2025年4月15日

/PRNewswire/ -- Volta Medical, a pioneering health technology company developing artificial intelligence (AI) solutions to assist electrophysiologists in assessing complex cardiac arrhythmias such as atrial fibrillation (AF), today announced presentations to be made at the Heart Rhythm Society 2025 meeting in .

/PRNewswire/ -- Volta Medical是一家开创性的健康技术公司，致力于开发人工智能（AI）解决方案，以协助电生理学家评估复杂的心律失常如心房颤动（AF）。该公司今天宣布将在2025年心律协会会议上进行相关展示。

San Diego

圣地亚哥

，

April 24 to 27

4月24日至27日

. In-person attendance and live online participation in a hybrid format will be available. These presentations include a Rhythm Theater featuring a panel of experts in the field. Volta's co-founder Dr. Clément Bars will present additional findings from the landmark TAILORED-AF clinical trial. Dr.

现场出席和在线实时参与的混合形式将会提供。这些报告包括一个节奏剧场，展示该领域专家小组的讨论。沃尔塔公司的联合创始人克莱门特·巴尔斯博士将介绍具有里程碑意义的TAILORED-AF临床试验的更多结果。

John Hummel

约翰·胡梅尔

, an electrophysiologist at

，一位电生理学家在

Ohio State University

俄亥俄州立大学

Wexner Medical Center and the primary investigator for the RESTART trial will present the trial's initial outcomes.

Wexner医学中心和RESTART试验的主要研究者将介绍该试验的初步结果。

Summary of Presentations:

演示文稿摘要：

Title

标题

Primary Author/Moderator

主要作者/主持人

Session Title

会议标题

Time (PST)

时间（太平洋标准时间）

Location

位置

Friday, April 25, 2025

2025年4月25日，星期五

Re-Ablation in Patients with Documented Isolated Veins Using a Tailored Approach Targeting Electrogram-Dispersion: The RESTART trial

使用针对电图分散的定制方法对有明确孤立静脉记录的患者进行再次消融：RESTART试验

Hummel, J

汉默尔，J

High Impact Science: Novel Technologies and Approaches in Catheter Ablation

高影响力科学：导管消融的新技术和方法

11:57am-12:05pm

上午11点57分至中午12点05分

Room 30A-E

房间 30A-E

AI-Driven Innovation in AF Ablation Procedures

人工智能驱动的房颤消融手术创新

Reddy, V

雷迪，V

AI-Driven Innovation in AF Ablation Procedures

人工智能驱动的房颤消融手术创新

1:15pm-2:15pm

下午1点15分至2点15分

Rhythm Theater 2

节奏剧场 2

Tailored Ablation for Atrial Fibrillation Guided by AI: The Tailored AF Trial

AI引导下的房颤消融术：Tailored AF试验

Bars, C

酒吧，C

How AI Can Facilitate Diagnosis and Catheter Ablation of Arrhythmias

人工智能如何促进心律失常的诊断和导管消融

2:15pm-2:27pm

下午2点15分至下午2点27分

Room 25A-C

房间 25A-C

Volta Medical will spotlight its latest clinical and technological advancements at Heart Rhythm 2025 in a Rhythm Theater session, 'AI-Driven Innovation in AF Ablation Procedures.' The session will be moderated by Dr.

Volta Medical 将在2025年心律协会年会的心律剧场环节“房颤消融手术中的人工智能驱动创新”上，重点展示其最新的临床和技术进展。该环节将由博士主持。

Vivek Reddy

维韦克·雷迪

of The Mount Sinai Hospital and feature expert panelists Dr. Tina Baykaner of

西奈山医院的专家小组成员包括蒂娜·巴伊坎尔博士

Stanford Medicine

斯坦福医学院

, Dr.

，博士。

Paul Zei

保罗·泽伊

of Brigham and Women's Hospital, and Dr.

布里格姆妇女医院的，以及博士。

Benjamin D'Souza

本杰明·德索萨

of Penn Presbyterian Medical Center. The panel will discuss the expanding role of AI in complex AF cases, and the integration of pulsed field ablation.

宾夕法尼亚长老会医疗中心。专家组将讨论人工智能在复杂房颤病例中日益扩大的作用，以及脉冲场消融的整合。

Dr.

博士

John Hummel

约翰·胡梅尔

will present acute and long-term outcomes from the RESTART trial, an international, multicenter, non-randomized interventional study evaluating outcomes in recurrent-AF patients who failed previous ablations and who are now undergoing Volta AI-guided ablation, to assess if patients will be AF-free, without antiarrhythmic drugs, 12 months after their procedure.

将介绍 RESTART 试验的急性和长期结果，这是一项国际性、多中心、非随机干预性研究，评估之前消融失败的复发性房颤患者在接受 Volta AI 引导的消融后的结果，以评估患者在术后 12 个月是否能在不使用抗心律失常药物的情况下无房颤。

This trial focuses on patients whose previous pulmonary vein isolation (PVI) is shown to still be isolated, which is a particularly difficult patient population to treat..

本试验重点关注之前肺静脉隔离 (PVI) 仍显示为隔离状态的患者，这是一个特别难以治疗的患者群体。

Volta Co-founder Dr. Clément Bars will present new insights from the TAILORED-AF trial, a transatlantic, randomized controlled study that demonstrated the superiority of Volta's AI-guided strategy plus PVI over PVI alone in patients with persistent and long-standing persistent AF. His presentation will delve into how artificial intelligence was utilized throughout the trial, provide an overview of the evolution of the Volta AF-Xplorer™ technology across its different versions, and explain how the AF-Xplorer platform functions.

Volta联合创始人克莱门特·巴尔斯博士将介绍TAILORED-AF试验的新见解。这项跨大西洋的随机对照研究证明了在持续性和长期持续性房颤患者中，Volta的AI引导策略加肺静脉隔离（PVI）优于单独使用PVI。他的演讲将深入探讨人工智能在试验中的应用，概述Volta AF-Xplorer™技术在不同版本中的演变，并解释AF-Xplorer平台的功能。

These findings further highlight Volta's innovative and differentiated approach to treating a patient population often underserved by conventional ablation strategies..

这些发现进一步突显了Volta在治疗常被传统消融策略服务不足的患者群体时，所采用的创新且差异化的方法。

At booth #1511, Volta Medical will showcase live demonstrations of the AF-Xplorer, an AI companion that identifies spatio-temporal dispersed electrograms (EGMs). Designed to support clinical decision-making in complex ablations, AF-Xplorer represents a significant step forward in scalable, data-driven treatment of persistent AF—supporting Volta's growth in a large, global electrophysiology market..

在1511号展位，Volta Medical将现场演示AF-Xplorer，这是一款识别时空分散电图（EGMs）的人工智能助手。AF-Xplorer旨在支持复杂消融术中的临床决策，代表了在持续性房颤的可扩展、数据驱动治疗方面迈出了重要一步，助力Volta在全球大型电生理市场中的增长。

About Atrial Fibrillation

关于心房颤动

The American Heart Association (AHA) defines atrial fibrillation (AF) as a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications.

美国心脏协会 (AHA) 将心房颤动 (AF) 定义为一种可能导致血栓、中风、心力衰竭和其他心脏相关并发症的颤动或不规则心跳（心律失常）。

Approximately 33 million patients worldwide are living with AF.

全球大约有3300万名房颤患者。

2,3

Even though untreated AF doubles the risk of heart-related deaths and is associated with a 5-fold increased risk for stroke, many patients are unaware that AF is a serious condition.

尽管未经治疗的房颤使心脏病相关死亡风险加倍，并且与中风风险增加 5 倍相关，但许多患者并未意识到房颤是一种严重的疾病。

About Volta Medical

关于沃尔塔医疗

Volta Medical is a health technology company developing artificial intelligence software solutions with the aim of assisting cardiac electrophysiologists during arrhythmia treatment procedures to improve clinical outcomes for patients. Founded by three physicians and a data scientist in 2016 in

Volta Medical是一家健康技术公司，致力于开发人工智能软件解决方案，旨在心律失常治疗过程中协助心脏电生理学家，以改善患者的临床结果。该公司由三位医生和一位数据科学家于2016年成立。

Marseille, France

法国马赛

, the company's mission is to improve cardiac arrhythmia management by developing state-of-the-art, data-driven medical devices trained on large databases of procedural data. The Volta AF-Xplorer is a digital AI companion designed to assist cardiologists with real-time identification of specific abnormal electrograms (EGMs) known as spatio-temporal dispersed EGMs during AF and atrial tachycardia procedures.

，该公司的使命是通过开发基于大型手术数据库训练的最先进的数据驱动型医疗设备，改善心脏心律失常管理。Volta AF-Xplorer 是一款数字 AI 助手，旨在帮助心脏病学家在房颤和房性心动过速手术过程中实时识别特定的异常电图（EGMs），即时空分散 EGMs。

The AF-Xplorer has been engineered for versatility and its use has been demonstrated with the most popular AF mapping and recording systems, as well as with the most common ablation modalities. The solution is U.S. FDA 510(k) cleared and European CE Mark approved. Volta Medical has created a therapy awareness program AI for Persistent AF Care designed to educate the underserved AF patient community, for more information, visit .

AF-Xplorer 已被设计为具有多功能性，其应用已经在最流行的 AF 标测和记录系统以及最常见的消融模式中得到验证。该解决方案已获得美国 FDA 510(k) 许可和欧洲 CE 认证。Volta Medical 创建了一个名为“AI for Persistent AF Care”的治疗意识计划，旨在教育服务不足的 AF 患者群体，欲了解更多信息，请访问。

www.aiforafib.com

。

Media Contact

媒体联系人

Molly Megna, Sr.

莫莉·梅格纳，高级

Marketing Manager

营销经理

Volta Medical

伏尔塔医疗

molly.megna@volta-medical.com

莫莉·梅格纳@伏尔塔医疗.com

References

参考文献

https://www.heart.org/en/health-topics/atrial-fibrillation

https://www.heart.org/zh/health-topics/atrial-fibrillation

[last accessed

[最后访问

June 9, 2023

2023年6月9日

]

2. Colilla S, Crow A, Petku W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 2013; 112:1142–1147. DOI: 10.1016/j.amjcard.2013.05.063

2. Colilla S, Crow A, Petku W, Singer DE, Simon T, Liu X. 美国成年人群中房颤发病率和患病率的当前及未来估算。《美国心脏病学杂志》2013年；112:1142–1147。DOI: 10.1016/j.amjcard.2013.05.063

https://kompetenznetz-vorhofflimmern.de/en

https://kompetenznetz-vorhofflimmern.de/zh

[last accessed

[最后访问

June 9, 2023

2023年6月9日

]

SOURCE Volta Medical

来源：伏打医疗

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻